World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

Autoimmunity BioSolutions Expands Seed Funding Round and Deepens Family Office Participation

Cision PR Newswire by Cision PR Newswire
May 13, 2026
in Press Releases - Lifestyle
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

New Capital Positions ABS to Reach Key Clinical Milestones and Advance Its Immuno-Corrective Autoimmune Therapy Platform

HOUSTON, May 13, 2026 /PRNewswire/ — Autoimmunity BioSolutions (ABS), a biotechnology company developing a personalized, genetically-guided immuno-corrective therapy designed to normalize elevated levels of soluble IL7 receptor (sIL7R), today announced the close of a $1M seed extension financing round, bringing total seed capital raised to $3.1 million. The round was anchored by lead investor Eos BioInnovation and a select group of family offices whose long-term investment orientation reflects strong conviction in ABS’s differentiated scientific platform and its potential to transform outcomes for the millions of autoimmune patients inadequately served by current therapies.


Next Generation, Immuno-Corrective Therapy for Autoimmune Disease Treatment (PRNewsfoto/Autoimmunity BioSolutions)

The round includes continued participation from existing investors EOS BioInnovation, Independent Capital and Elmstead Partners, reflecting strong ongoing confidence in the ABS platform. ABS also welcomes NewTech Investment Holdings to the round as a new family office investor. Their participation anchors the $1M seed extension.

“We are grateful for the continued support of our family office partners, whose participation in this seed extension reflects shared belief in the transformative potential of our platform,” said Eugene Williams, MBA, Chief Executive Officer, Autoimmunity BioSolutions. “With the participation of seasoned investors who understand the pace and promise of life sciences innovation, we are well-positioned to deploy this capital with purpose, completing important animal model work and patient bio-sample analyses in our lead indication of Rheumatoid Arthritis, building on the compelling scientific momentum already underway at ABS.”

Advancing a Genetically Targeted Approach to Autoimmune Disease

ABS’s scientific team has identified a highly prevalent SNP, estimated to be present in roughly 50% of the overall population, which causes a 2–3-fold increase in circulating sIL7R. Elevated sIL7R has been repeatedly shown in scientific evidence to contribute to greater disease severity, increased disease progression, and reduced response to standard-of-care therapies across multiple autoimmune indications, including rheumatoid arthritis (RA), lupus nephritis (LN), and type 1 diabetes (T1D).

About Autoimmunity BioSolutions (ABS)

Autoimmunity BioSolutions (ABS) is pioneering a personalized, genetically guided immuno-corrective therapy designed to normalize or “correct” elevated levels of soluble IL7 receptor (sIL7R), a fundamental driver of poor therapeutic response in autoimmune disease. This therapy targets a genetically defined subpopulation of autoimmune disease patients marked by a highly prevalent genetic variant (SNP) that elevates the expression of sIL7R and is associated with greater severity of disease, increased progression of disease, and poor response to current treatments. This immuno-corrective approach of targeting sIL7R in a genetic population is highly differentiated from current standards of care that rely on immunosuppressive mechanisms and has broad potential to enhance response to standards of care in the refractory population with elevated sIL7R across numerous autoimmune diseases. For more information, visit www.abstherapeutics.com or follow us on LinkedIn.

For investor inquiries, please contact:

Jen Beachell
Chief Business Officer
jen@abstherapeutics.com

For media inquiries, please contact:
Madelyn De Los Santos
Putnam Insights
Madelyn@putnaminsights.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/autoimmunity-biosolutions-expands-seed-funding-round-and-deepens-family-office-participation-302770302.html

SOURCE Autoimmunity BioSolutions

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • RADICL Names Former Huntress CRO Mike LaPeters Chief Revenue Officer to Scale Autonomous Cyber Defense

    0 shares
    Share 0 Tweet 0
  • ISM Names Smith+Nephew Global Head of Procurement Jami Bliss to Board of Directors

    0 shares
    Share 0 Tweet 0
  • LSEG Finance plc announces cash tender offer for up to U.S.$165,000,000 in aggregate principal amount of its U.S.$1,250,000,000 2.500% Notes due 2031

    0 shares
    Share 0 Tweet 0
  • Homera Launches First-of-its-Kind AI Mortgage Platform to Remove Confusion and Stress Out of Buying and Owning a Home

    0 shares
    Share 0 Tweet 0
  • Republic of Peru Announces Results of Exchange Offers

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler